In vitro activities of 16 antimicrobial agents against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in two regional hospitals in Taiwan

Journal of Microbiology, Immunology and Infection

Volumn 39, Issue 1, 2006, Pages 59-66

  Liao, Chun Hsing ^a   Sheng, Wang Huei ^a   Wang, Jann Tay ^a   Sun, Hsin Yun ^a   Wang, Hua Kung ^b   Hsueh, Po Ren ^a   Chen, Yee Chun ^a   Chang, Shan Chwen ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b EN CHU KONG HOSPITAL   (Taiwan)

Author keywords

Aminoglycosides; Beta lactamases; Carbapenems; Cephalosporins; Cephamycins; Fluoroquinolones

Indexed keywords

AMIKACIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CARBAPENEM; CEFEPIME; CEFIXIME; CEFMETAZOLE; CEFOTAXIME; CEFPODOXIME; CEFTIBUTEN; CIPROFLOXACIN; ERTAPENEM; FLOMOXEF; GENTAMICIN; IMIPENEM; ISEPAMICIN; MEROPENEM; PANIPENEM; ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; ESCHERICHIA COLI; HOSPITAL; HOSPITAL POLICY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; TAIWAN; ANTIBIOTIC RESISTANCE; DRUG EFFECT; ENTEROBACTER INFECTION; ENZYMOLOGY; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HOSPITALS; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; TAIWAN;

EID: 33645316143     PISSN: 16841182     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Gold HS, Moellering RC Jr. Antimicrobial-drug resistance. N Eng J Med 1996;335:1445-53.
2. Philippen A, Labia R, Jacoby G. Extended-spectrum β-lactamases. Antimicrob Agents Chemother 1989;33:1131-6.
3. Jacoby GA, Medeiros AA. More extended-spectrum β-lactamases. Antimicrob Agents Chemother 1991;35:1697-704.
4. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum β-lactamase production in nosocomial infections. Ann Intern Med 2004;140:26-32.
5. Hsueh PR, Liu CY, Luh KT. Current status of antimicrobial resistance in Taiwan. Emerg Infect Dis 2002;8:132-7.
6. Jean SS, Teng LJ, Hsueh PR, Ho SW, Luh KT. Antimicrobial susceptibilities among clinical isolates of extended-spectrum cephalosporin-resistant Gram-negative bacteria in a Taiwanese University Hospital. J Antimicrob Chemother 2002;49:69-76.
7. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum β-lactamases. Clin Infect Dis 2003;39: 31-7.
8. Rahal JJ, Urban C, Horn D, Freeman K, Segal-Maurer S, Maurer J, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocominal Klebsiella. JAMA 1998;280:1233-7.
9. Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, et al. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 2004;48:4574-81.
10. Paterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs). Clin Microbiol Infect 2000; 6:460-3.
11. Paterson DL, Mulazimoglu L, Casellas JM, Ko WC, Goossens H, Von Gottberg AV, et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum β-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 2000;30:473-8.
12. Lautenbach E, Strom BL, Bilker WB, Patel JB, Edelstein PH, Fishman NO. Epidemiological investigation of flouroquinolone resistance in infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin Infect Dis 2001;33:1288-94.
13. Yu WL, Jones RN, Hollis RJ, Messer SA, Biedenbach DJ, Deshpande LM, et al. Molecular epidemiology of extended-spectrum β-lactamase-producing, fluoroquinolone-resistant isolates of Klebsiella pneumoniae in Taiwan. J Clin Microbiol 2002;40:4666-9.
14. Tolun V, Kucukbasmaci O, Torumkuney-Akbulut D, Catal C, Ang-Kucuker M, Ang O. Relationship between ciprofloxacin resistance and extended-spectrum β-lactamase production in Escherichia coli and Klebsiella pneumoniae strains. Clin Microbiol Infect 2004;10:72-5.
15. Yu WL, Chuang YC, Jones RN. A pragmatic approach to identify extended-spectrum β-lactamase-producing Klebsiella pneumoniae in Taiwan: in vitro activity of newer and established antimicrobial agents. Diagn Microbiol Infect Dis 2004;48: 277-82.
16. Yu WL, Pfaller MA, Winokur PL, Jones RN. Cefepime MIC as a predictor of the extended-spectrum β-lactamase type in Klebsiella pneumoniae, Taiwan. Emerg Infect Dis 2002;8: 522-4.
17. Jacoby GA, Han P. Detection of extended-spectrum β-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli. J Clin Microb 1996;34:908-11.
18. Pangon B, Bizet C, Bure A, Pichon F, Philippen A, Regnier B, et al. In vivo selection of a cephamycin-resistant, porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 β-lactamase. J Infect Dis 1989;159:1005-6.
19. Yang CC, Chuang FR, Hsu KT, Chen JB, Lee CH, Lee CT, et al. Expanded-spectrum beta-lactamase producing Klebsiella pneumoniae-related peritonitis in a patient on peritoneal dialysis. Am J Kidney Dis 2004;44:e102-6.
20. Bedenic B, Vranes J, Suto S, Zagar Z. Bactericidal activity of oral beta-lactam antibiotics in plasma and urine versus isogenic Escherichia coli strains producing broad- and extended-spectrum beta-lactamases. Int J Antimicrob Agents 2005;25: 479-87.
21. Livermore DM, Oakton KJ, Carter MW, Warner M. Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent beta-lactamases. Antimicrob Agents Chemother 2001; 45:2831-7.
22. Nakamura T, Komatsu M. Susceptibility of ESBL-producing Escherichia coli and Klebsiella pneumoniae to various antibacterial agents. Jpn J Antibiot 2005;58:1-10. [In Japanese; English abstract].
23. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disc susceptibility. Approved standard, 7th edition. M2-A8. Wayne (PA): NCCLS; 2004.
24. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 5th edition. M7-A6. Wayne (PA): NCCLS; 2004.
25. Chang SC, Fang CT, Hsueh PR, Chen YC, Luh KT. Klebsiella pneumoniae isolates causing liver abscess in Taiwan. Diagn Microbiol Infect Dis 2000;37:279-84.
26. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995;33: 2233-9.
27. Jan IS, Hsueh PR, Teng LJ, Ho SW, Luh KT. Antimicrobial susceptibility testing for Klebsiella pneumoniae isolates resistant to extended-spectrum β-lactam antibiotics. J Formos Med Assoc 1998;97:661-6.
28. Biedenbach DJ, Johnson DM, Jones RN. In vitro evaluation of cefepime and other broad-spectrum β-lactams in Taiwan medical centers. The Taiwan Antimicrobial Resistance Study Group. Diagn Microbiol Infect Dis 1999;35:299-305.
29. Jones RN, Biedenbach DJ, Gales AC. Sustained activity and spectrum of selected extended-spectrum β-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY antimicrobial surveillance program (USA, 1997-2000). Int J Antimicrob Agents 2003;21:1-7.
30. Livermore DM, Mushtaq S, Warner M. Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems. J Antimicrob Chemother. 2005;55:306-11.
31. Matsumoto T, Muratani T. Newer carbapenems for urinary tract infections. Int J Antimicrob Agents 2004;24 Suppl 1:S35-8.
32. Ena J, Lopez-Perezagua MM, Martinez-Peinado C, Cia-Barrio MA, Ruiz-Lopez I. Emergence of ciprofloxacin resistance in Escherichia coli isolates after widespread use of flouroquinolones. Diagn Microbiol Infect Dis 1998;30:103-7.
33. Sheng WH, Chen YC, Wang JT, Chang SC, Luh KT, Hsieh WC. Emerging fluoroquinolone-resistance for common clinically important gram-negative bacteria in Taiwan. Diagn Microbiol Infect Dis 2002;43:141-7.
34. Rice LB, Yao JD, Klimm K, Eliopoulos GM, Moellering RC Jr. Efficacy of different β-lactams against an extended-spectrum β-lactamase-producing Klebsiella pneumoniae strain in the rat intra-abdominal abscess model. Antimicrob Agents Chemother 1991;35:1243-4.
35. Karas JA, Pillay DG, Muckart D, Sturm AW. Treatment failure due to extended spectrum β-lactamase. J Antimicrob Chemother 1996;37:203-4.
36. Thomson KS, Moland ES. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2001;45:3548-54.